Eric Curfman
Cleveland, OHNPI 1023694825
Payments from drug & device makers
$2,688in general payments, 2019–2025
Across 145 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$592
- AstraZeneca$439
- Novartis$247
- EMD Serono, Inc.$222
- SK Life Science, Inc.$175
- Lilly USA, LLC$152
- plus $861 from 16 others
What the payments were for
- Food & beverage$2,688100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 31 | $592 |
| AstraZeneca(2 entities) | 24 | $439 |
| Novartis | 13 | $247 |
| EMD Serono, Inc. | 15 | $222 |
| SK Life Science, Inc. | 10 | $175 |
| Lilly USA, LLC | 8 | $152 |
| Averitas Pharma Inc. | 6 | $138 |
| Jazz Pharmaceuticals Inc. | 7 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $131 |
| Genentech USA, Inc. | 4 | $78 |
| TG Therapeutics, Inc. | 3 | $59 |
| Sanofi | 3 | $57 |
| Amgen(2 entities) | 3 | $47 |
| Lundbeck LLC | 2 | $38 |
| AbbVie | 2 | $30 |
| Pfizer | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| CSL Behring | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Amylyx Pharmaceuticals, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.